Tpl2 kinase signal transduction in inflammation and cancer

Cancer Letters

Volumn 304, Issue 2, 2011, Pages 80-89

  Vougioukalaki, Maria ^a   Kanellis, Dimitris C ^a   Gkouskou, Kalliopi ^a   Eliopoulos, Aristides G ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

ABIN2; Cancer; Cot kinase; IKK ; Inflammation; MAP3K8; NF B1; Tnip2; Tpl2

Indexed keywords

A20 BINDING INHIBITOR OF NUCLEAR FACTOR KAPPA B 2; CD40 ANTIGEN; CELL PROTEIN; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR KAPPA B 1; PROTEIN P105; PROTEIN SERINE THREONINE KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR PROGRESSION LOCUS 2 KINASE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CARCINOGENESIS; CELL FUNCTION; CHRONIC INFLAMMATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 79952738601     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.004     Document Type: Review

References (85)

1. Dumitru C.D., Ceci J.D., Tsatsanis C., Kontoyiannis D., Stamatakis K., Lin J.H., Patriotis C., Jenkins N.A., Copeland N.G., Kollias G., Tsichlis P.N. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000, 103:1071-1083.
2. Eliopoulos A.G., Dumitru C.D., Wang C.-C., Cho J., Tsichlis P.N. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 2002, 21:4831-4840.
3. Hall J.P., Kurdi Y., Hsu S., Cuozzo J., Liu J., Telliez J.B., Seidl K.J., Winkler A., Hu Y., Green N., Askew G.R., Tam S., Clark J.D., Lin L.L. Pharmacologic inhibition of Tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J. Biol. Chem. 2007, 282:33295-33304.
4. Kakimoto K., Musikacharoen T., Chiba N., Bandow K., Ohnishi T., Matsuguchi T. Cot/Tpl2 regulates IL-23 p19 expression in LPS-stimulated macrophages through ERK activation. J. Physiol. Biochem. 2010, 66:47-53.
5. Mielke L.A., Elkins K.L., Wei L., Starr R., Tsichlis P.N., O'Shea J.J., Watford W.T. Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J. Immunol. 2009, 183:7984-7993.
6. Rousseau S., Papoutsopoulou M., Symons A., Cook D., Lucocq J.M., Prescott A.R., O'Garra A., Ley S.C., Cohen P. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J. Cell Sci. 2008, 121:149-154.
7. Xiao N., Eidenschenk C., Krebs P., Brandl K., Blasius A.L., Xia Y., Khovananth K., Smart N.G., Beutler B. The Tpl2 mutation Sluggish impairs type I IFN production and increases susceptibility to group B streptococcal disease. J. Immunol. 2009, 183:7975-7983.
8. Eliopoulos A.G., Wang C.C., Dumitru C.D., Tsichlis P.N. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. Embo J. 2003, 22:3855-3864.
9. Das S., Cho J., Lambertz I., Kelliher M.A., Eliopoulos A.G., Du K., Tsichlis P.N. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J. Biol. Chem. 2005, 280:23748-23757.
10. Banerjee A., Gugasyan R., McMahon M., Gerondakis S. Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc. Natl. Acad. Sci. USA 2006, 103:3274-3279.
11. Stafford M.J., Morrice N.A., Peggie M.W., Cohen P. Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett. 2006, 580:4010-4014.
12. Cusack K., Allen H., Bischoff A., Clabbers A., Dixon R., Fix-Stenzel S., Friedman M., Gaumont Y., George D., Gordon T., Grongsaard P., Janssen B., Jia Y., Moskey M., Quinn C., Salmeron A., Thomas C., Wallace G., Wishart N., Yu Z. Identification of a selective thieno[2, 3-c]pyridine inhibitor of COT kinase and TNF-alpha production. Bioorg. Med. Chem. Lett. 2009, 19:1722-1725.
13. Sugimoto K., Ohata M., Miyoshi J., Ishizaki H., Tsuboi N., Masuda A., Yoshikai Y., Takamoto M., Sugane K., Matsuo S., Shimada Y., Matsuguchi T. A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. J. Clin. Invest. 2004, 114:857-866.
14. Kaiser F., Cook D., Papoutsopoulou S., Rajsbaum R., Wu X., Yang H.T., Grant S., Ricciardi-Castagnoli P., Tsichlis P.N., Ley S.C., O'Garra A. TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells. J. Exp. Med. 2009, 206:1863-1871.
15. Zacharioudaki V., Androulidaki A., Arranz A., Vrentzos G., Margioris A.N., Tsatsanis C. Adiponectin promotes endotoxin tolerance in macrophages by inducing IRAK-M expression. J. Immunol. 2009, 182:6444-6451.
16. Makris A., Patriotis C., Bear S.E., Tsichlis P.N. Structure of a Moloney murine leukemia virus-virus-like 30 recombinant: implications for transduction of the c-Ha-ras proto-oncogene. J. Virol. 1993, 67:1286-1291.
17. Watford W.T., Hissong B.D., Durant L.R., Yamane H., Muul L.M., Kanno Y., Tato C.M., Ramos H.L., Berger A.E., Mielke L., Pesu M., Solomon B., Frucht D.M., Paul W.E., Sher A., Jankovic D., Tsichlis P.N., O'Shea J.J. Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii. J. Exp. Med. 2008, 205:2803-2812.
18. Watford W.T., Wang C.C., Tsatsanis C., Mielke L.A., Eliopoulos A.G., Daskalakis C., Charles N., Odom S., Rivera J., O'Shea J., Tsichlis P.N. Ablation of tumor progression locus 2 promotes a type 2 Th cell response in Ovalbumin-immunized mice. J. Immunol. 2010, 184:105-113.
19. Banerjee A., Grumont R., Gugasyan R., White C., Strasser A., Gerondakis S. NF-kappaB1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms. Blood 2008, 112:5063-5073.
20. Kontoyiannis D., Boulougouris G., Manoloukos M., Armaka M., Apostolaki M., Pizarro T., Kotlyarov A., Forster I., Flavell R., Gaestel M., Tsichlis P., Cominelli F., Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J. Exp. Med. 2002, 196:1563-1574.
21. Ohnishi T., Okamoto A., Kakimoto K., Bandow K., Chiba N., Matsuguchi T. Involvement of Cot/Tp12 in bone loss during periodontitis. J. Dent. Res. 2010, 89:192-197.
22. Van Acker G.J., Perides G., Weiss E.R., Das S., Tsichlis P.N., Steer M.L. Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis. J. Biol. Chem. 2007, 282:22140-22149.
23. Yaomura T., Tsuboi N., Urahama Y., Hobo A., Sugimoto K., Miyoshi J., Matsuguchi T., Reiji K., Matsuo S., Yuzawa Y. Serine/threonine kinase, Cot/Tpl2, regulates renal cell apoptosis in ischaemia/reperfusion injury. Nephrology (Carlton) 2008, 13:397-404.
24. Gafencu A.V., Robciuc M.R., Fuior E., Zannis V.I., Kardassis D., Simionescu M. Inflammatory signaling pathways regulating ApoE gene expression in macrophages. J. Biol. Chem. 2007, 282:21776-21785.
25. Jager J., Gremeaux T., Gonzalez T., Bonnafous S., Debard C., Laville M., Vidal H., Tran A., Gual P., Le Marchand-Brustel Y., Cormont M., Tanti J.F. Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes 2009, 59:61-70.
26. Patriotis C., Makris A., Bear S.E., Tsichlis P.N. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc. Natl. Acad. Sci. USA 1993, 90:2251-2255.
27. Erny K.M., Peli J., Lambert J.F., Muller V., Diggelmann H. Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene 1996, 13:2015-2020.
28. Miyoshi J., Higashi T., Mukai H., Ohuchi T., Kakunaga T. Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol. Cell Biol. 1991, 11:4088-4096.
29. Ceci J.D., Patriotis C.P., Tsatsanis C., Makris A.M., Kovatch R., Swing D.A., Jenkins N.A., Tsichlis P.N., Copeland N.G. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev. 1997, 11:688-700.
30. Velasco-Sampayo A., Alemany S. P27kip protein levels and E2F activity are targets of Cot kinase during G1 phase progression in T cells. J. Immunol. 2001, 166:6084-6090.
31. Tsatsanis C., Patriotis C., Tsichlis P.N. Tpl-2 induces IL-2 expression in T cell lines by triggering multiple signaling pathways that activate NFAT and NF-κB. Oncogene 1998, 17:2609-2618.
32. Clark A.M., Reynolds S.H., Anderson M., Wiest J.S. Mutational activation of the MAP3K8 protooncogene in lung cancer. Genes Chromosomes Canc. 2004, 41:99-108.
33. Shirali S., Hamoudi R.A., Bench A., Scott M., Ley S.C., Du M.Q. TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia. Leuk. Res. 2007, 31:1604-1607.
34. Ohara R., Hirota S., Onoue H., Nomura S., Kitamura Y., Toyoshima K. Identification of the cells expressing COT proto-oncogene messenger RNA. J. Cell. Sci. 1995, 108:97-103.
35. Christoforidou A.V., Papadaki H.A., Margioris A.N., Eliopoulos G.D., Tsatsanis C. Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol. Canc. 2004, 3:34.
36. Sourvinos G., Tsatsanis C., Spandidos D.A. Over-expression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 1999, 18:4968-4973.
37. Krcova Z., Ehrmann J., Krejci V., Eliopoulos A., Kolar Z. Tpl-2/Cot and COX-2 in breast cancer. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2008, 152:21-25.
38. Eliopoulos A.G., Davies C., Blake S.S., Murray P., Najafipour S., Tsichlis P.N., Young L.S. The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2. J. Virol. 2002, 76:4567-4579.
39. Jeong J.H., Bhatia A., Toth Z., Oh S., Inn K.S., Liao C.P., Roy-Burman P., Melamed J., Coetzee G.A., Jung J.U. TPL2/COT/MAP3K8 (TPL2) Activation Promotes Androgen Depletion-Independent (ADI) Prostate Cancer Growth. PLoS One 2011, 6:e16205.
40. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., Caponigro G., Hieronymus H., Murray R.R., Salehi-Ashtiani K., Hill D.E., Vidal M., Zhao J.J., Yang X., Alkan O., Kim S., Harris J.L., Wilson C.J., Myer V.E., Finan P.M., Root D.E., Roberts T.M., Golub T., Flaherty K.T., Dummer R., Weber B.L., Sellers W.R., Schlegel R., Wargo J.A., Hahn W.C., Garraway L.A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
41. Ovcharenko D., Kelnar K., Johnson C., Leng N., Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007, 67:10782-10788.
42. Babu G., Waterfield M., Chang M., Wu X., Sun S.C. Deregulated activation of oncoprotein kinase Tpl2/Cot in HTLV-I-transformed T cells. J. Biol. Chem. 2006, 281:14041-14047.
43. Li X., Feng J., Chen S., Peng L., He W.W., Qi J., Deng H., Sun R. Tpl2/AP-1 enhances murine gammaherpesvirus 68 lytic replication. J. Virol. 2009, 84:1881-1890.
44. Tsatsanis C., Vaporidi K., Zacharioudaki V., Androulidaki A., Sykulev Y., Margioris A.N., Tsichlis P.N. Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells. Proc. Natl. Acad. Sci. USA 2008, 105:2987-2992.
45. Decicco-Skinner K.L., Trovato E.L., Simmons J.K., Lepage P.K., Wiest J.S. Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis. Oncogene 2011, 30:389-397.
46. Salmeron A., Ahmad T.B., Carlile G.W., Pappin D., Narsimhan R.P., Ley S.C. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 1996, 15:817-826.
47. Chiariello M., Marinissen M.J., Gutkind J.S. Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol. Cell Biol. 2000, 20:1747-1758.
48. Tsatsanis C., Patriotis C., Bear S.E., Tsichlis P.N. The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and induces interleukin 2 expression in T cells. Proc. Natl. Acad. Sci. USA 1998, 95:3827-3832.
49. Gomez-Casero E., San-Antonio B., Iniguez M.A., Fresno M. Cot/Tpl2 and PKCzeta cooperate in the regulation of the transcriptional activity of NFATc2 through the phosphorylation of its amino-terminal domain. Cell Signal 2007, 19:1652-1661.
50. Lin X., Cunningham E.T., Mu Y., Geleziunas R., Greene W.C. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-κB acting through the NF-κB-inducing kinase and IκB kinases. Immunity 1999, 10:271-280.
51. Choi H.S., Kang B.S., Shim J.H., Cho Y.Y., Choi B.Y., Bode A.M., Dong Z. Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity. Faseb J. 2008, 22:113-126.
52. Khanal P., Lee K.Y., Kang K.W., Kang B.S., Choi H.S. Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF. Carcinogenesis 2009, 30:682-689.
53. Gandara M.L., Lopez P., Hernando R., Castano J.G., Alemany S. The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity. Mol. Cell Biol. 2003, 23:7377-7390.
54. Waterfield M.R., Zhang M., Norman L.P., Sun S.C. NF-kappaB1/p105 Regulates Lipopolysaccharide-Stimulated MAP Kinase Signaling by Governing the Stability and Function of the Tpl2 Kinase. Mol. Cell 2003, 11:685-694.
55. Beinke S., Deka J., Lang V., Belich M.P., Walker P.A., Howell S., Smerdon S.J., Gamblin S.J., Ley S.C. NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol. Cell Biol. 2003, 23:4739-4752.
56. K. Hirata, H. Taki, K. Shinoda, H. Hounoki, T. Miyahara, K. Tobe, H. Ogawa, H. Mori, and E. Sugiyama, Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes. Biol. Pharm. Bull. vol. 33, pp. 133-137.
57. Hatziapostolou M., Polytarchou C., Panutsopulos D., Covic L., Tsichlis P.N. Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res. 2008, 68:1851-1861.
58. Belich M.P., Salmeron A., Johnston L.H., Ley S.C. Tpl-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105. Nature 1999, 397:363-368.
59. Beinke S., Robinson M.J., Hugunin M., Ley S.C. Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IkappaB kinase-induced proteolysis of NF-kappaB1 p105. Mol. Cell Biol. 2004, 24:9658-9667.
60. Waterfield M., Jin W., Reiley W., Zhang M., Sun S.C. IkappaB kinase is an essential component of the Tpl2 signaling pathway. Mol. Cell Biol. 2004, 24:6040-6048.
61. Cho J., Tsichlis P.N. Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and Tpl2 activation and degradation by lipopolysaccharide. Proc. Natl. Acad. Sci. USA 2005, 102:2350-2355.
62. Robinson M.J., Beinke S., Kouroumalis A., Tsichlis P.N., Ley S.C. Phosphorylation of TPL-2 on serine 400 is essential for lipopolysaccharide activation of extracellular signal-regulated kinase in macrophages. Mol. Cell Biol. 2007, 27:7355-7364.
63. Babu G.R., Jin W., Norman L., Waterfield M., Chang M., Wu X., Zhang M., Sun S.C. Phosphorylation of NF-kappaB1/p105 by oncoprotein kinase Tpl2: implications for a novel mechanism of Tpl2 regulation. Biochim. Biophys. Acta 2006, 1763:174-181.
64. Lang V., Symons A., Watton S.J., Janzen J., Soneji Y., Beinke S., Howell S., Ley S.C. ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability. Mol. Cell Biol. 2004, 24:5235-5248.
65. Papoutsopoulou S., Symons A., Tharmalingham T., Belich M.P., Kaiser F., Kioussis D., O'Garra A., Tybulewicz V., Ley S.C. ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses. Nat. Immunol. 2006, 7:606-615.
66. Eliopoulos A.G., Das S., Tsichlis P.N. The tyrosine kinase Syk regulates TPL2 activation signals. J. Biol. Chem. 2006, 281:1371-1380.
67. Devin A., Lin Y., Liu Z.G. The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep. 2003, 4:623-627.
68. Devin A., Cook A., Lin Y., Rodriguez Y., Kelliher M., Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000, 12:419-429.
69. Cho J., Melnick M., Solidakis G.P., Tsichlis P.N. Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals. J. Biol. Chem. 2005, 280:20442-20448.
70. Mieulet V., Yan L., Choisy C., Sully K., Procter J., Kouroumalis A., Krywawych S., Pende M., Ley S.C., Moinard C., Lamb R.F. TPL-2-mediated activation of MAPK downstream of TLR4 signaling is coupled to arginine availability. Sci. Signal 2010, 3:ra61.
71. Hacker H., Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006, 2006:13.
72. Rodriguez C., Pozo M., Nieto E., Fernandez M., Alemany S. TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell Signal 2006, 18:1376-1385.
73. Black T.M., Andrews C.L., Kilili G., Ivan M., Tsichlis P.N., Vouros P. Characterization of phosphorylation sites on Tpl2 using IMAC enrichment and a linear ion trap mass spectrometer. J. Proteome. Res. 2007, 6:2269-2276.
74. Pomeroy S.L., Tamayo P., Gaasenbeek M., Sturla L.M., Angelo M., McLaughlin M.E., Kim J.Y., Goumnerova L.C., Black P.M., Lau C., Allen J.C., Zagzag D., Olson J.M., Curran T., Wetmore C., Biegel J.A., Poggio T., Mukherjee S., Rifkin R., Califano A., Stolovitzky G., Louis D.N., Mesirov J.P., Lander E.S., Golub T.R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436-442.
75. Yusenko M.V., Kuiper R.P., Boethe T., Ljungberg B., van Kessel A.G., Kovacs G. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 2009, 9:152.
76. D'Errico M., de Rinaldis E., Blasi M.F., Viti V., Falchetti M., Calcagnile A., Sera F., Saieva C., Ottini L., Palli D., Palombo F., Giuliani A., Dogliotti E. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur. J. Cancer 2009, 45:461-469.
77. Sperger J.M., Chen X., Draper J.S., Antosiewicz J.E., Chon C.H., Jones S.B., Brooks J.D., Andrews P.W., Brown P.O., Thomson J.A. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc. Natl. Acad. Sci. USA 2003, 100:13350-13355.
78. Beroukhim R., Brunet J.P., Di Napoli A., Mertz K.D., Seeley A., Pires M.M., Linhart D., Worrell R.A., Moch H., Rubin M.A., Sellers W.R., Meyerson M., Linehan W.M., Kaelin W.G., Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009, 69:4674-4681.
79. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., Lai K.M., Ji J., Dudoit S., Ng I.O., Van De Rijn M., Botstein D., Brown P.O. Gene expression patterns in human liver cancers. Mol. Biol. Cell 2002, 13:1929-1939.
80. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
81. Basso K., Margolin A.A., Stolovitzky G., Klein U., Dalla-Favera R., Califano A. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 2005, 37:382-390.
82. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., Lin L., Chen G., Gharib T.G., Thomas D.G., Lizyness M.L., Kuick R., Hayasaka S., Taylor J.M., Iannettoni M.D., Orringer M.B., Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002, 8:816-824.
83. Anderson K.C., Kyle R.A., Rajkumar S.V., Stewart A.K., Weber D., Richardson P., Myeloma A.F.P.o.C.E.i.M. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008, 22:231-239.
84. Su L.J., Chang C.W., Wu Y.C., Chen K.C., Lin C.J., Liang S.C., Lin C.H., Whang-Peng J., Hsu S.L., Chen C.H., Huang C.Y. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 2007, 8:140.
85. Sanchez-Carbayo M., Socci N.D., Lozano J., Saint F., Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 2006, 24:778-789.